

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9966)**

## **VOLUNTARY ANNOUNCEMENT COMPLETION OF CONSTRUCTION OF THE PHASE I MANUFACTURING FACILITIES**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the construction of the phase I of the new manufacturing facilities of the Company (the “**Phase I Manufacturing Facilities**”) is completed in December 2019. The Phase I Manufacturing Facilities are located at No. 175, Fangzhou Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, People’s Republic of China with a 4,000L (2x2,000L) production capacity.

The Phase I Manufacturing Facilities are currently in the process of commissioning and qualification and about to commence the production trial run.

The Company will make further announcements in relation to the manufacturing facilities as and when appropriate and/or required under the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited.

### **ABOUT THE MANUFACTURING FACILITIES OF THE COMPANY**

The Company is in the process of building its own manufacturing and research and development facilities in Suzhou designed to meet National Medical Products Administration and European Union/U.S. Food & Drug Administration’s current good manufacturing practice requirements with an expected capacity of over 30,000L. Phase I of the new facilities has a commercial production capacity of 4,000L (2x2,000L) and a planned gross floor area of 53,867 square meters. The new manufacturing facilities are supported by the comprehensive in-house quality management system. The Company has equipped its large-scale production with advanced technology platforms, CMC processes and know-how.

## **ABOUT THE COMPANY**

The Company is a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house pipeline of the Company consists of eight oncology drug candidates, including four in the phase I-III clinical trial development stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional bio-macromolecule new drugs that benefit patients globally.

**Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.**

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, December 18, 2019

*As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.*